PURPOSE Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. PATIENTS AND METHODS We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients enrolled onto the study. Overall response rates were 88%, 93%, and 91% for R-CVP, R-CHOP, and R-FM, respectively (P=.247). After a median follow-up of 34 months, 3-year TTFs were 46%, 62%, and 59% for the respective treatment groups (R-CHOP v R-CVP, P=.003; R-FM v R-CVP, P=.006; R-FM v R-CHOP, P=.763). Three-year progression-free survival (PFS) rates were 52%, 68%, and 63% (overall P=.011), respectively, and 3-year overall survival was 95% for the whole series. R-FM resulted in higher rates of grade 3 to 4 neutropenia (64%) compared with R-CVP (28%) and R-CHOP (50%; P< .001). Overall, 23 second malignancies were registered during follow-up: four in R-CVP, five in R-CHOP, and 14 in R-FM. CONCLUSION In this study, R-CHOP and R-FM were superior to R-CVP in terms of 3-year TTF and PFS. In addition, R-CHOP had a better risk-benefit ratio compared with R-FM.
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi / Federico, Massimo; Luminari, Stefano; Dondi, Alessandra; Tucci, Alessandra; Vitolo, Umberto; Rigacci, Luigi; Di Raimondo, Francesco; Carella, Angelo Michele; Pulsoni, Alessandro; Merli, Francesco; Arcaini, Luca; Angrilli, Francesco; Stelitano, Caterina; Gaidano, Gianluca; Dell'Olio, Matteo; Marcheselli, Luigi; Franco, Vito; Galimberti, Sara; Sacchi, Stefano; Brugiatelli, Maura. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 31 (12)(2013), pp. 1506-1513. [10.1200/JCO.2012.45.0866]
Data di pubblicazione: | 2013 | |
Titolo: | R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi | |
Autore/i: | Federico, Massimo; Luminari, Stefano; Dondi, Alessandra; Tucci, Alessandra; Vitolo, Umberto; Rigacci, Luigi; Di Raimondo, Francesco; Carella, Angelo Michele; Pulsoni, Alessandro; Merli, Francesco; Arcaini, Luca; Angrilli, Francesco; Stelitano, Caterina; Gaidano, Gianluca; Dell'Olio, Matteo; Marcheselli, Luigi; Franco, Vito; Galimberti, Sara; Sacchi, Stefano; Brugiatelli, Maura | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1200/JCO.2012.45.0866 | |
Rivista: | ||
Volume: | 31 (12) | |
Pagina iniziale: | 1506 | |
Pagina finale: | 1513 | |
Codice identificativo ISI: | WOS:000317831500012 | |
Codice identificativo Scopus: | 2-s2.0-84876578455 | |
Codice identificativo Pubmed: | 23530110 | |
Citazione: | R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi / Federico, Massimo; Luminari, Stefano; Dondi, Alessandra; Tucci, Alessandra; Vitolo, Umberto; Rigacci, Luigi; Di Raimondo, Francesco; Carella, Angelo Michele; Pulsoni, Alessandro; Merli, Francesco; Arcaini, Luca; Angrilli, Francesco; Stelitano, Caterina; Gaidano, Gianluca; Dell'Olio, Matteo; Marcheselli, Luigi; Franco, Vito; Galimberti, Sara; Sacchi, Stefano; Brugiatelli, Maura. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 31 (12)(2013), pp. 1506-1513. [10.1200/JCO.2012.45.0866] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
JCO-2013-Federico-1506-13.pdf | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris